Effects of compound danshen extract on bone histomorphometry of high-fat rats

doi:10.3969/j.issn.2095-4344.2013.02.005

Abstract

Abstract:

BACKGROUND: Compound danshen extract can inhibit bone resorption and rival bone loss of rats induced by prednisone. However, there are no reports indicating its effectiveness in osteoporosis induced by hyperlipidemia.
OBJECTIVE:To study the effect of compound danshen extract against tibia and lumbar spine bone loss by using bone histomorphometry through establishing a osteoporosis rat model induced by high-fat emulsion.
METHODS: Thirty 3-month-old male Sprague-Dawley rats were randomly divided into normal saline group, high-fat emulsion group, compound danshen extract group. Rats were sacrificed after 16 weeks.
RESULTS AND CONCLUSION: Compared with the high-fat emulsion group, serum total cholesterol decreased and high-density lipoprotein cholesterol increased significantly following treatment with compound danshen extract. In the longitudinal proximal tibial metaphyseal of rats treated with compound danshen extract, %Tb.Ar, Tb.N and %Ob.S.Pm increased (P < 0.05), while Tb.Sp, %Oc.S.Pm and Oc.N/mm decreased (P < 0.01). In the tibial shaft, %Ct.Ar increased (P < 0.01), while %Ma.Ar decreased (P < 0.01). In the fifth lumbar vertebral body, %Tb.Ar, Tb.N and Tb.Th increased (P < 0.05), while Tb.Sp decreased (P < 0.01). Long-term high-fat diets can cause the loss of bone in rats, and compound danshen extract can prevent these changes through stimulating periosteal bone formation.

Key words: tissue construction, bone tissue construction, high-fat emulsion, compound danshen, osteoporosis, bone histomorphometry, rats, National Natural Science Foundation of China, tissue construction photographs- containing paper

CLC Number:

R318

Zhang Xin-le, Wu Tie, Cui Liao, Xu Bi-lian. Effects of compound danshen extract on bone histomorphometry of high-fat rats[J]. Chinese Journal of Tissue Engineering Research, 2013, 17(2): 210-216.

Figures/Tables 13

References

[1] Xu J, Zhao DB, Liu WB. Zhongguo Quanke Yixue. 2010; 13(11): 1246-1248.许洁,赵东宝,刘文斌.老年性骨质疏松症的防治进展[J].中国全科医学,2010,13(11):1246-1248.

[2] Chen GF, Zhang LH, Chen ZJ. Fangshe Mianyixue Zazhi. 2009;22(5):489-490.陈国富,张腊红,陈兆军.骨质疏松症患者血清骨钙素与血脂的相关性分析[J].放射免疫学杂志,2009,22(5):489-490.

[3] You TT, Wu T, Zhang ZP, et al. Zhongguo Linchuang Yaolixue yu Zhiliaoxue. 2007;12(3):299-303.尤婷婷,吴铁,张志平,等.高脂血症致大鼠骨质疏松作用研究初探[J].中国临床药理学与治疗学,2007,12(3):299-303.

[4] Zhang LH, Huang GM. Zhongguo Shiyong Yixue. 2010;5(18): 74-75.张俐虹,黄国民.复方丹参滴丸对高血压患者血脂代谢及CRP 的影响[J].中国实用医药,2010,5(18):74-75.

[5] Feng JB, Chen HY, Sun W. Shandong Yiyao. 2009;49(9):43.冯静波,陈洪颖,孙伟.复方丹参滴丸对高脂血症患者血脂水平的影响[J].山东医药,2009,49(9):43.

[6] Li XP, Zhao SP, Qin YN. Zhongxiyi Jiehe Xinnaoxueguanbing Zazhi. 2010;8(11):1283-1285.李向平,赵水平,秦英楠.复方丹参滴丸对冠心病及其高危患者血脂及大动脉弹性的影响[J].中西医结合心脑血管病杂志,2010, 8(11): 1283-1285.

[7] Chinese Pharmacopoeia Commission. Chemical Industry Press. 2000:518.国家药典委员会编.中华人民共和国药典(2000年版一部)[S].北京:化学工业出版社,2000:518.

[8] Zhang XL, Wu T, Cui L, et al. Zhongguo Zuzhi Gongcheng Yanjiu yu Linchuang Kangfu. 2010;14(28):5141-5145.张新乐,吴铁,崔燎,等.复方司坦唑醇对D-半乳糖大鼠不同部位骨骼的影响[J].中国组织工程研究与临床康复,2010,14(28): 5141-5145.

[9] Zhang ZP, You TT, Zou LY, et al. Nanfang Yike Daxue Xuebao. 2008;28(9):550-1553.张志平,尤婷婷,邹丽宜,等.复方丹参合剂对高脂血症性骨质疏松小鼠血脂、骨生物力学的影响[J].南方医科大学学报,2008,28(9): 1550-1553.

[10] Parhami F, Garfinkel A, Demer LL. Role of lipids in osteoporosis. Arterioscler Thromb Vasc Biol. 2000;20(11):2346-2348.

[11] Kajkenova O, Lecka-Czernik B, Gubrij I, et al. Increased adipogenesis and myelopoiesis in the bone marrow of SAMP6, a murine model of defective osteoblastogenesis and low turnover osteopenia. J Bone Miner Res. 1997;12(11):1772-1779.

[12] Sakaguchi K, Morita I, Murota S. Relationship between the ability to support differentiation of osteoclast like cells and adipogenesis in murine stromal cells derived from bone marrow. Prostaglandins Leukot Essent Fatty Acids. 2000; 62(5): 319-327.

[13] Zhang MY, Yuan XG, Meng FC. Zhongguo Shiyong Shenjing Jibing Zazhi. 2011;14(4):75-76.张明艳,袁小庚,孟凡超.洛伐他汀联合复方丹参滴丸治疗高脂血症临床观察[J].中国实用神经疾病杂志,2011,14(4):75-76.

[14] Liu XY, Zhou L, Wang PX. Zhonghua Zhongyiyao Xuekan. 2011;29(2):369-371.刘新迎,周联,王培训.以3T3-L1细胞模型探讨部分丹参提取物的调脂机制[J].中华中医药学刊,2011,29(2):369-371.

[15] Liu HY, Tian S. Yaowu yu Linchuang. 2009;47(24):124-125.刘红玉,田爽.复方丹参滴丸对高血脂患者血液流变学的影响[J].药物与临床,2009,47(24):124-125.

[16] Tang ZL, Zhang HP, Li Y, et al. Hubei Zhongyi Zazhi. 2008; 30(6):11-12.汤治黎,章汉平,李源,等.丹参注射液诱导大鼠骨髓间充质干细胞分化为成软骨细胞的研究[J].湖北中医杂志,2008,30(6):11-12.